Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00018 | sulfo-SPDB-DM4 | 1626359-59-8 |
| DM4 with a reactive linker sulfo-SPDB, which can react with antibody to make antibody drug conjugate. DM4 can bind to tubulin at or near the vinblastine-binding site. | Inquiry | |
| BADC-00019 | Fmoc-VC-PAB-MMAE | 1350456-56-2 |
| Fmoc-Val-Cit-PAB-MMAE is an antibody drug conjugate contained Fmoc-Val-Cit-PAB and MMAE and probably have antineoplastic activity. | Inquiry | |
| BADC-00024 | Vc-MMAD | 1401963-17-4 |
| Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate. | Inquiry | |
| BADC-00026 | Mc-MMAD | 1401963-15-2 |
| Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAD is a protective group (maleimidocaproyl) -conjugated MMAD. | Inquiry | |
| BADC-00027 | INNO-206 | 1361644-26-9 |
| INNO-206 (Aldoxorubicin) is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. | Inquiry | |
| BADC-00028 | DOXO-EMCH | 151038-96-9 |
| DOXO-EMCH is an albumin-binding prodrug of doxorubicin, which is an anthracycline antibiotic with anti-Gram-positive bacterial activity and a broad antitumor spectrum. | Inquiry | |
| BADC-00030 | BA-3011 | |
| BA-3011 is a novel conditionally active biologic AXL-targeted antibody-drug conjugate used to treat solid tumor. The CAB technology is aimed to improve the selectivity of BA-3011 for binding to AXL receptor on cancer cells. | Inquiry | |
| BADC-00574 | Lys-SMCC-DM1 | 1281816-04-3 |
| Lys-SMCC-DM1 is the active metabolite of DM1. DM1 is a tubulin inhibitor. | Inquiry | |
| BADC-00585 | Vc-seco-DUBA | 1345681-58-4 |
| Vc-seco-DUBA is a drug-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco. | Inquiry | |
| BADC-00592 | MC-Alkyl-Hydrazine Modified MMAF | 1404071-64-2 |
| MC-Alkyl-Hydrazine Modified MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine. | Inquiry | |
| BADC-00594 | PEG4-aminooxy-MMAF | 1415246-35-3 |
| PEG4-aminooxy-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4. | Inquiry | |
| BADC-00596 | AcLys-PABC-VC-Aur0101 | 1438851-17-2 |
| AcLys-PABC-VC-Aur0101 is a cleavable anti-CXCR4 drug-linker conjugates for ADC. It has potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC. | Inquiry | |
| BADC-00600 | Sulfo-PDBA-DM4 | 1461704-01-7 |
| Sulfo-PDBA-DM4 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody drug conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker. | Inquiry | |
| BADC-00601 | Mal-VC-PAB-DM1 | 1464051-44-2 |
| Mal-VC-PAB-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB. | Inquiry | |
| BADC-00604 | Mal-C6-α-Amanitin | 1578249-76-9 |
| Mal-C6-α-Amanitin is a drug-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6. | Inquiry | |
| BADC-00608 | MC-GGFG-DX8951 | 1600418-29-8 |
| MC-GGFG-DX8951 is a DX8951 derivative with MC-GGFG linker, in which DX8951 was covalently connected via a peptidyl spacer (Gly-Gly-Phe-Gly), which is assumed to be stable in circulation, and were cleaved by lysosomal enzymes following ADC internalization into tumor tissue. MC-GGFG-DX8951 is very useful to prepare DX8951 antibody conjugate (ADC). | Inquiry | |
| BADC-00611 | MC-Val-Cit-PAB-clindamycin | 1639793-13-7 |
| MC-Val-Cit-PAB-clindamycin is a drug-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB. | Inquiry | |
| BADC-00612 | MC-Val-Cit-PAB-Retapamulin | 1639793-15-9 |
| MC-Val-Cit-PAB-retapamulin has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Val-Cit-PAB-retapamulin is used for the antibody-drug conjugates (ADC) that are effective and stable in vitro and in vivo to treat various diseases or disorders. | Inquiry | |
| BADC-00613 | AmPEG6C2-Aur0131 | 1650569-94-0 |
| AmPEG6C2-Aur0131 is a drug-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2. | Inquiry | |
| BADC-00619 | AZ1508 | 1817736-04-1 |
| AZ1508 is a drug-linker conjugates for ADC for the treatment of breast and stomach cancer, and the drug is a tubulin inhibitor. | Inquiry |
